Lozol

(Indapamide)

ApprovedSmall molecule

Sanofi

Lozol is one of 90 small molecule programs targeting Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

HypertensionActive, not recruiting

Heart FailureActive, not recruiting

Renal InsufficiencyActive, not recruiting

HypertensionPhase 2

Active, not recruiting

Heart FailureApproved

Active, not recruiting

Renal InsufficiencyApproved

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Lozol

Sanofi

Approved

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

LCZ696

Novartis

Preclinical

15 4

Monoferric

PPharmacosmos A/S

Preclinical

5 5

Savaysa

Xifaxan

2 7

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 8

Statin

Bristol-Myers Squibb

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Thiazolidinediones

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Kidney Stone

NCT06111885

Clinical

Trials by Indication[1]

Heart Failure1 trial

The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT04455178·200 enrolled

Type 2 DM1 trial

A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM

Completed·LLaborMed Pharma S.A.·Phase 4·NCT00980187·56 enrolled

Spironolactone1 trial

Spironolactone Versus Indapamide in Obese and Hypertensive Patients

Unknown status·PPeking University Third Hospital·N/A·NCT03626506·400 enrolled

Renal insufficiency1 trial

Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency

Completed·WWest China Hospital·Phase 4·NCT01172431·240 enrolled

Hypertension1 trial

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

Completed· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Phase 2·NCT05103332·663 enrolled

2 more indications

Blood Pressure1 trial

IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs

Completed·HHospices Civils de Lyon·Phase 4·NCT00128518·139 enrolled

Kidney Stone1 trial

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention

Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT06111885·99 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 29, 1993

LOZOL

NDA NDA018538

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Indapamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Indapamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Indapamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018538). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Lozol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Heart Failure1 trial

Type 2 DM1 trial

Spironolactone1 trial

Renal insufficiency1 trial

Hypertension1 trial

Blood Pressure1 trial

Kidney Stone1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News